A child with severe hearing loss associated with maternal cisplatin treatment during pregnancy

Eric C T Geijteman; Celesta W M Wensveen; Johannes J Duvekot; Lia van Zuylen

doi:10.1097/AOG.0000000000000389

A child with severe hearing loss associated with maternal cisplatin treatment during pregnancy

Eric C T Geijteman, Celesta W M Wensveen, Johannes J Duvekot, Lia van Zuylen

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: Cisplatin is considered safe to use during the second and third trimesters of pregnancy in patients with cancer.

CASE: A 34-year-old pregnant woman was diagnosed with cervical cancer. She received five weekly dosages of cisplatin and paclitaxel, starting at 26 5/7 weeks of gestation. An elective cesarean delivery was performed at 34 4/7 weeks of gestation. After birth, the neonate was diagnosed with severe bilateral perceptive hearing loss.

CONCLUSION: Cisplatin during the second and third trimesters of pregnancy may lead to fetal ototoxicity.

Original language	English
Pages (from-to)	454-6
Number of pages	3
Journal	Obstetrics and Gynecology
Volume	124
Issue number	2 Pt 2 Suppl 1
DOIs	https://doi.org/10.1097/AOG.0000000000000389
Publication status	Published - Aug 2014
Externally published	Yes

Access to Document

10.1097/AOG.0000000000000389

Cite this

@article{f09c16494fc54d7c82919a5ce2e61f5e,

title = "A child with severe hearing loss associated with maternal cisplatin treatment during pregnancy",

abstract = "BACKGROUND: Cisplatin is considered safe to use during the second and third trimesters of pregnancy in patients with cancer.CASE: A 34-year-old pregnant woman was diagnosed with cervical cancer. She received five weekly dosages of cisplatin and paclitaxel, starting at 26 5/7 weeks of gestation. An elective cesarean delivery was performed at 34 4/7 weeks of gestation. After birth, the neonate was diagnosed with severe bilateral perceptive hearing loss.CONCLUSION: Cisplatin during the second and third trimesters of pregnancy may lead to fetal ototoxicity.",

keywords = "Adult, Antineoplastic Agents/adverse effects, Carcinoma, Squamous Cell/drug therapy, Cisplatin/adverse effects, Female, Hearing Loss, Bilateral/chemically induced, Humans, Infant, Newborn, Male, Pregnancy, Pregnancy Complications, Neoplastic/drug therapy, Severity of Illness Index, Uterine Cervical Neoplasms/drug therapy",

author = "Geijteman, {Eric C T} and Wensveen, {Celesta W M} and Duvekot, {Johannes J} and {van Zuylen}, Lia",

year = "2014",

month = aug,

doi = "10.1097/AOG.0000000000000389",

language = "English",

volume = "124",

pages = "454--6",

journal = "Obstetrics and Gynecology",

issn = "0029-7844",

publisher = "Lippincott Williams and Wilkins",

number = "2 Pt 2 Suppl 1",

}

TY - JOUR

T1 - A child with severe hearing loss associated with maternal cisplatin treatment during pregnancy

AU - Geijteman, Eric C T

AU - Wensveen, Celesta W M

AU - Duvekot, Johannes J

AU - van Zuylen, Lia

PY - 2014/8

Y1 - 2014/8

N2 - BACKGROUND: Cisplatin is considered safe to use during the second and third trimesters of pregnancy in patients with cancer.CASE: A 34-year-old pregnant woman was diagnosed with cervical cancer. She received five weekly dosages of cisplatin and paclitaxel, starting at 26 5/7 weeks of gestation. An elective cesarean delivery was performed at 34 4/7 weeks of gestation. After birth, the neonate was diagnosed with severe bilateral perceptive hearing loss.CONCLUSION: Cisplatin during the second and third trimesters of pregnancy may lead to fetal ototoxicity.

AB - BACKGROUND: Cisplatin is considered safe to use during the second and third trimesters of pregnancy in patients with cancer.CASE: A 34-year-old pregnant woman was diagnosed with cervical cancer. She received five weekly dosages of cisplatin and paclitaxel, starting at 26 5/7 weeks of gestation. An elective cesarean delivery was performed at 34 4/7 weeks of gestation. After birth, the neonate was diagnosed with severe bilateral perceptive hearing loss.CONCLUSION: Cisplatin during the second and third trimesters of pregnancy may lead to fetal ototoxicity.

KW - Adult

KW - Antineoplastic Agents/adverse effects

KW - Carcinoma, Squamous Cell/drug therapy

KW - Cisplatin/adverse effects

KW - Female

KW - Hearing Loss, Bilateral/chemically induced

KW - Humans

KW - Infant, Newborn

KW - Male

KW - Pregnancy

KW - Pregnancy Complications, Neoplastic/drug therapy

KW - Severity of Illness Index

KW - Uterine Cervical Neoplasms/drug therapy

U2 - 10.1097/AOG.0000000000000389

DO - 10.1097/AOG.0000000000000389

M3 - Article

C2 - 25004323

VL - 124

SP - 454

EP - 456

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 2 Pt 2 Suppl 1

ER -